Helsinki-based healthtech company Gosta Labs has closed an oversubscribed €7.5 million seed round, bringing the company’s total funding to nearly €10 million. The round was led by Voima Ventures, with support from COR Group, the Aho family, and Reaktor.
- Established in 2023 by Lauri Sippola and Henri Viertolahti, Gosta Labs develops an AI operating system designed for complex medical specialties, with a focus on oncology.
- The system captures and structures clinical data from each patient encounter in real time, automating documentation and summarizing patient journeys.
- By converting unstructured clinical notes into high-quality structured data, the platform supports decision-making, links care decisions to international guidelines, and tracks key clinical parameters such as Performance Status and CTCAE toxicity grades.
- In practice, the AI reduces the administrative burden on clinicians, enabling faster, more consistent documentation and allowing healthcare professionals to devote more time to direct patient care. The platform is currently deployed across healthcare providers in Finland, Switzerland, the Baltics, and Australia.
Details of the deal
- Gosta Labs plans to use the €7.5 million seed funding to expand its AI operating system to oncology teams worldwide, further strengthen its medical-device-grade product and AI foundation, and enhance patient care by enabling safer and more personalized interactions.
- The funding will also help reduce clinicians’ administrative workload, allowing oncologists to spend more time with patients while maintaining high-quality, guideline-driven care.
“Gosta Labs’ key team members combine proven startup execution, deep domain expertise and top notch AI capabilities. They’ve done it before and know what good looks like, which is an essential for any startup team. There’s a lot of hype around AI but Gosta delivers the value it promises and customers love the product," claims Jussi Sainiemi, Partner at Voima Ventures.
